About ALK-Abello
ALK-Abello is a company based in Hørsholm (Denmark) founded in 1923. The company has 2,750 employees. ALK-Abello has completed 2 acquisitions, including Bio-Medical Services and Crystal Laboratory. ALK-Abello offers products and services including Allergy Vaccines, Diagnostics, and Consumer Healthcare. ALK-Abello operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Dren Bio and Vividion Therapeutics, among others.
- Annual Revenue$992.68 M (USD)14as on Dec 31, 2025
- Net Profit$188.78 M (USD)46.87as on Dec 31, 2025
- EBITDA$311.49 M (USD)45.66as on Dec 31, 2025
- Latest Funding Round$110.72M (USD), Post-IPO
Dec 2017
- Investors
- Employee Count2,750
- Investments & AcquisitionsBio-Medical Services
& 1 more
Products & Services of ALK-Abello
ALK-Abello offers a comprehensive portfolio of products and services, including Allergy Vaccines, Diagnostics, and Consumer Healthcare.
Vaccines for treating allergies like pollen and dust mites.
Tools for diagnosing various types of allergies.
Products for managing everyday allergy symptoms.
Funding Insights of ALK-Abello
- Total Rounds 2
- Last Round Post-IPO — $110.72M
- First Round $35M
(Jan 2007)
- Investors Count 1
All 2 funding rounds of ALK-Abello with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $110.72M | Post-IPO | – | – | – |
| Jan 2007 | $35M | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in ALK-Abello
ALK-Abello has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom |
Investor details for ALK-Abello
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ALK-Abello
276 people are tracked at ALK-Abello (90 in leadership, 11 in board & advisors, 175 in team); the tracked headcount is 2,750.
| Name | Role | Group |
|---|---|---|
Carsten Hellmann | CEO & President | Leadership |
Jennie Zhong | China General Manager | Leadership |
Jay Bates | Executiver Director, Allergy Extract, Diagnostics & Life Science Business Units | Leadership |
Scott Maloney | Associate Director, Extract & Diagnostic Sales | Leadership |
Philip Væring Petersen | General Manager | Leadership |
Stacie Tardif | Associate Director, New Product Planning And Portfolio Strategy (food Allergy Therapy Area) | Leadership |
Georg Borup | Sales & Operations Director | Leadership |
Morten Mølskov Jarlstrup | Corporate Strategy Director | Leadership |
Rasmus Just | Global Head Business Development | Leadership |
Anna Derejska | Senior Manager, Performance Reporting And Global Marketing Business Partner | Leadership |
Sidsel Birch Andersen | Interim Head Of Digital Customer Engagement & Digital Excellence | Leadership |
Christina Brown | Senior Lead Business Partner, People & Organization | Leadership |
Ghassan Qutob | Regional General Manager | Leadership |
Ida Smith | Director, Clinical Reporting | Leadership |
Claus Steensen Sølje | EVP & CFO | Leadership |
Jennifer Bennett | Senior Director Medical Affairs, North America | Leadership |
Timothy Davis | Vice President, GM | Leadership |
Dr. Janina Mette | Vice President, Global Marketing And Market Access | Leadership |
Stig Møller Christensen | Senior Director, Global Life Cycle Management, Global Marketing, Partner Markets & China | Leadership |
Jacob Glenting | Senior Vice President Of Global Strategy And Corporate Development | Leadership |
256 more people are available in the full profile.
Complete people profiles for ALK-Abello
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ALK-Abello
ALK-Abello is a publicly listed company on the OMXCOP with ticker symbol ALK_B in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Mar 2000
- Listed onNASDAQ: ALK-B
- Listed entityALK-abello A/S Class B
- Exchange sectorHealth technology
- ISINDK0061802139
- Share price227.40 DKK (-0.35% on the day) · 2026-10-09
- Market capitalisation50,799,839,639.00 DKK
- Price to earnings37.2
- EPS (diluted, trailing year)6.12 DKK
- Dividend yield0.7%
- Volume (last session)251,746
Financials of ALK-Abello
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 6.31B DKK | 1.20B DKK | 1.98B DKK |
| 2024 | 5.54B DKK | 815.0M DKK | 1.36B DKK |
| 2023 | 4.82B DKK | 486.0M DKK | 909.0M DKK |
| 2022 | 4.51B DKK | 335.0M DKK | 707.0M DKK |
| 2021 | 3.92B DKK | 219.0M DKK | 533.0M DKK |
Detailed financial statements for ALK-Abello
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ALK-Abello
ALK-Abello has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bio-Medical Services and Crystal Laboratory.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufacturer of allergy medicines | crystallabsllc.com | – | 1968 | Dec 2016 | •••• | |
Veterinary health products are provided by Bio-Medical Services. | bmslab.com | Austin, United States | 1999 | Mar 2014 | •••• |
Complete acquisition details for ALK-Abello
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ALK-Abello
6 dated milestones of ALK-Abello across 94 years, from founding to its latest funding, stage changes and deals.
- Founded ALK-Abello is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $35.0M.
- Acquisition Acquires Bio-Medical Services.
- Acquisition Acquires Crystal Laboratory.
- Funding Latest funding round, Post-IPO, of $110.7M.
Competitors of ALK-Abello
ALK-Abello operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Dren Bio and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| drenbio.com | 2019 | San Carlos, United States | $131M | – | Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. |
Detailed competitors of ALK-Abello
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ALK-Abello
The website of ALK-Abello (alk.net) receives about 43.7K visits a month and ranks #855,421 among all websites worldwide, #1,028 in Biotechnology and Pharmaceuticals.
- Monthly visits43.7K
▲ 22% vs previous month
- Unique visitors14.8K
per month
- Global rank#855,421
among all websites
- Category rank#1,028
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.9
- Average visit1 min 03 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with ALK-Abello. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| stallergenesgreer.com | 100% | 13.4K | #1,596,150 | View details | |
andreaskalcker.com | andreaskalcker.com | 77% | – | #534,170 | – |
mgr.farm | mgr.farm | 58% | – | #211,193 | – |
strefaalergii.pl | strefaalergii.pl | 58% | – | #1,269,856 | – |
Latest news on Alk-Abello
Complete news archive for ALK-Abello
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ALK-Abello
10 companies that operate in the same segment as ALK-Abello (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ALK-Abello
ALK-Abello was founded in 1923 and raised its 1st funding round 84 years after it was founded.
ALK-Abello is headquartered in Hørsholm, Denmark.
Carsten Hellmann is the current CEO of ALK-Abello.
ALK-Abello has 2,750 employees.
Annual revenue of ALK-Abello is $992.68M as on Dec 31, 2025.
ALK is a Danish, Public Biopharma company developing allergy immunotherapies including injections (emergency) and sublingual tablets. As on Nov 2016, they are in Phase III trials for sublingual allergy tablets for house dust mite, Japanese cedar and tree pollen. They have already marketed sublingual tablets for grass and ragweed. They also manufacture adrenaline auto-injections for anaphylaxis.
ALK-Abello's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
ALK-Abello offers Allergy Vaccines, Diagnostics, and Consumer Healthcare.
Yes, ALK-Abello is publicly traded on OMXCOP under the ticker symbol ALK_B.
ALK-Abello has made 2 acquisitions, including Bio-Medical Services, and Crystal Laboratory.
ALK-Abello has 1 investor. Key investors include Merck.
ALK-Abello operates through Alk E-Com A/S.